Stocks · Health care · Pharmaceutical Preparations

Serina Therapeutics, Inc.

SER Clue Score38
United States Fiscal year ends December CIK 0001708599 Results filed 13 Aug 2026

What the insiders did Net buying

By person

11 insiders · 84 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Randall Moreadith
Chief Scientific Officer
—
$1.12M (41) scheduled
−$1.12M
0
$0.00
—
Gregory Bailey
Director
$504.76K (16)
—
+$504.76K
8,564,382
$17.39M
+3,171,893%
Steven Mintz
Director
$289.47K (14)
—
+$289.47K
29,700
$60.29K
—
Karen J Wilson
Director
$54.75K (4)
—
+$54.75K
10,100
$20.50K
—
Richard Peter Marshall
Director
$20.10K (1)
—
+$20.10K
12,183
$24.73K
—
Michael D West
Chief Executive Officer
$15.44K (1)
—
+$15.44K
41,982
$85.22K
+553.8%
Stephen K. Brannan
Director
$2.03K (1)
—
+$2.03K
1,000
$2.03K
—
Jay Venkatesan
Director
$1.05K (1)
—
+$1.05K
232,294
$471.56K
—
Juvenescence Ltd entity
10% owner
— (1)
—
$0.00
3,267,188
$6.63M
−82.2%
Steven A Ledger
Chief Executive Officer
—
—
—
10,100
$20.50K
—
Hal Sternberg
Vice President-Research
—
—
—
133
$269.99
0.0%

No percentages here. This company's share count has moved by a factor of 2.6 over the window, from 9,932,215 to 25,400,473 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.